Fresenius Medical Care AG

Helen Giza was appointed Chief Executive Officer effective December 6, 2022. She continued to serve as acting Chief Financial Officer until September 30, 2023. Helen Giza joined Fresenius Medical Care in 2019 as Chief Financial Officer and took on the additional role of Chief Transformation Officer heading the FME25 transformation program in 2021. Previously, she has been Chief Integration and Divestiture Management Officer at Takeda Pharmaceuticals since 2018. Before joining the Takeda Corporate Executive Team, she served as Chief Financial Officer of Takeda’s U.S. business unit since 2008. Prior to that she held a number of key international finance and controlling positions, amongst others at TAP Pharmaceuticals and Abbott Laboratories. Helen Giza is a U.K. Chartered Certified Accountant and holds a Master of Business Administration from the Kellogg School of Management at Northwestern University in Evanston, Illinois, USA.

CV

Craig Cordola was appointed Chief Executive Officer of Care Delivery and member of the Management Board as of January 1, 2024. Prior to joining Fresenius Medical Care, he served in several Executive roles with Ascension from 2017 through 2023, including, Executive Vice President for Ascension Capital, Executive Vice President and Chief Operating Officer, and President and Chief Executive Officer for Ascension Texas. Craig joined Fresenius Medical Care in 2024 and has almost 30 years of experience in the healthcare industry, holding Chief Executive Officer roles and other senior leadership positions at several healthcare organizations, including the Memorial Hermann Health System, The University of Texas Health Science Center at Houston, and Texas Children’s Hospital.

CV

Martin Fischer was appointed Chief Financial Officer and member of the Management Board as of October 1, 2023. In this role he is responsible for the global finance organization of Fresenius Medical Care. Prior to his appointment, he was Head of Finance for Siemens Healthineers’ Diagnostics division based in Tarrytown, NY, USA since 2019. Previously, he headed the Board Office and Organizations function for Siemens Healthineers after leading the business plan and operating model development for the company’s initial public offering in March 2018. Earlier in his career, he held a number of key international operational and finance positions in healthcare within Siemens AG. Martin Fischer holds a degree in business informatics from the Reutlingen University of Applied Sciences and an MBA from Friedrich Alexander University, Nuremberg, Germany. He completed the Chief Financial Officer Program at Columbia Business School in New York, USA.

CV

Franklin W. Maddux, MD was appointed Global Chief Medical Officer in 2019 and appointed to the Management Board on January 1, 2020. He is an expert nephrologist, IT entrepreneur and healthcare executive with more than 30 years of experience in healthcare. He joined the company in 2009 as Executive Vice President for Clinical & Scientific Affairs and Chief Medical Officer for Fresenius Medical Care North America, where he was responsible for the delivery of high-quality, value-based care for the largest integrated renal care network on the continent. His expertise and research interests have focused on quality care for chronic kidney disease patients around the world.

CV

Dr. Katarzyna Mazur-Hofsäß took over responsibility for the globally operating Care Enablement segment, in which Fresenius Medical Care is consolidating its healthcare products business under a global MedTech umbrella, effective January 1, 2022. Previously, she served as Chief Executive Officer for EMEA since September 1, 2018. Since 2013 she was president for EMEA at the med-tech company Zimmer Biomet. In her 25 years of professional career Katarzyna has gained extensive international experience in executive general management positions. She is a physician by educational background and holds a Ph.D. from Gdansk Medical University in Poland, as well as an MBA from the Warsaw School of Economics and the University of Minnesota.

CV